ES2119738T3 - Profarmacos de etoposido de glicosilo, procedimiento para su preparacion y su aplicacion en combinacion con conjugados enzimaticos funcionalizados, especificos de tumores. - Google Patents

Profarmacos de etoposido de glicosilo, procedimiento para su preparacion y su aplicacion en combinacion con conjugados enzimaticos funcionalizados, especificos de tumores.

Info

Publication number
ES2119738T3
ES2119738T3 ES90119886T ES90119886T ES2119738T3 ES 2119738 T3 ES2119738 T3 ES 2119738T3 ES 90119886 T ES90119886 T ES 90119886T ES 90119886 T ES90119886 T ES 90119886T ES 2119738 T3 ES2119738 T3 ES 2119738T3
Authority
ES
Spain
Prior art keywords
glycosyl
preparation
combination
ethoposide
functionalized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90119886T
Other languages
English (en)
Inventor
Cenek Dr Kolar
Jorg Dr Czech
Klaus Dr Bosslet
Gerhard Dr Seemann
Hans Harald Dr Sedlacek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Application granted granted Critical
Publication of ES2119738T3 publication Critical patent/ES2119738T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

EL INVENTO SE REFIERE A UN PRODUCTO DE PREDROGA A BASE DE ETOPOSIDO/GLICOSILO. TRATA DE UN PROCEDIMIENTO PARA LA OBTENCION DE PRODUCTOS PREDROGAS A BASE DE ETOPOSIDO/GLICOSILO; RESEÑA EL PRODUCTO DE PREDROGA A BASE DE 4'' ONJUGADOS ENZIMATICOS Y ESPECIFICOS DE TUMORES Y SE EMPLEA COMBINADO, CON CONJUGADOS ENZIMATICOS FUNCIONALIZADOS Y ESPECIFICOS DE TUMORES PARA EL TRATAMIENTO DE ENFERMEDADES CANCEROSAS.
ES90119886T 1989-10-20 1990-10-17 Profarmacos de etoposido de glicosilo, procedimiento para su preparacion y su aplicacion en combinacion con conjugados enzimaticos funcionalizados, especificos de tumores. Expired - Lifetime ES2119738T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3935016A DE3935016A1 (de) 1989-10-20 1989-10-20 Glycosyl-etoposid-prodrugs, verfahren zu ihrer herstellung und ihre anwendung in kombination mit funktionalisiertem tumorspezifischen enzym-konjugaten

Publications (1)

Publication Number Publication Date
ES2119738T3 true ES2119738T3 (es) 1998-10-16

Family

ID=6391872

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90119886T Expired - Lifetime ES2119738T3 (es) 1989-10-20 1990-10-17 Profarmacos de etoposido de glicosilo, procedimiento para su preparacion y su aplicacion en combinacion con conjugados enzimaticos funcionalizados, especificos de tumores.

Country Status (12)

Country Link
EP (1) EP0423747B1 (es)
JP (1) JP3293086B2 (es)
KR (1) KR910007948A (es)
AT (1) ATE168695T1 (es)
AU (1) AU638064B2 (es)
CA (1) CA2028086A1 (es)
DE (2) DE3935016A1 (es)
DK (1) DK0423747T3 (es)
ES (1) ES2119738T3 (es)
GR (1) GR3027569T3 (es)
IE (1) IE903764A1 (es)
PT (1) PT95620B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
US7241595B2 (en) * 1989-10-20 2007-07-10 Sanofi-Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
ATE177321T1 (de) * 1989-12-11 1999-03-15 Immunomedics Inc Verfahren zum aufspüren von diagnostischen oder therapeutischen mitteln durch antikörper
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
IT1250692B (it) * 1991-07-23 1995-04-21 Procedimento per la preparazione di demetilepipodofillotossina- beta-d-glucosidi.
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
DE19702988A1 (de) * 1997-01-28 1998-07-30 Hoechst Ag Isoxazol- und Crotonsäureamidderivate und deren Verwendung als Arzneimittel und Diagnostika
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
WO2001049693A1 (en) * 2000-01-03 2001-07-12 Korea Research Institute Of Chemical Technology 4-O-[2-(N,N-DIALKYLAMINO)-2-DEOXY-4,6-O,O-beta-D-GLUCOSYL]-4'-O-DEMETHYL-EPI-PODOPHYLLOTOXIN, DERIVATIVES, AND AN ANTICANCER COMPOSITION CONTAINING SAME
US20050009759A1 (en) * 2001-10-26 2005-01-13 Claude Monneret Derivatives of etoposide and analogs, and pharmaceutical compositions containing them
EP1451193B1 (en) 2001-12-03 2010-10-06 Universitätsklinikum Charité der Humboldt- Universität zu Berlin Podophyllotoxins as antiproliferative agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3329184A1 (de) * 1983-08-12 1985-02-21 Behringwerke Ag, 3550 Marburg Monoklonale antikoerper mit spezifitaet fuer membran-assoziierte antigene
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
DE4002888A1 (de) * 1990-02-01 1991-08-08 Behringwerke Ag Anthracyclin-glycosyl-prodrugs, verfahren zu ihrer herstellung und ihre verwendung in kombination mit funktionalisierten tumorspezifischen enzymkonjugaten

Also Published As

Publication number Publication date
JP3293086B2 (ja) 2002-06-17
PT95620A (pt) 1991-09-13
CA2028086A1 (en) 1991-04-21
EP0423747A3 (en) 1991-09-11
ATE168695T1 (de) 1998-08-15
EP0423747B1 (de) 1998-07-22
DE3935016A1 (de) 1991-04-25
DK0423747T3 (da) 1999-04-26
GR3027569T3 (en) 1998-11-30
EP0423747A2 (de) 1991-04-24
PT95620B (pt) 1997-08-29
AU6477890A (en) 1991-04-26
IE903764A1 (en) 1991-04-24
JPH03135993A (ja) 1991-06-10
DE59010838D1 (de) 1998-08-27
AU638064B2 (en) 1993-06-17
KR910007948A (ko) 1991-05-30

Similar Documents

Publication Publication Date Title
BR9814857A (pt) Processos para tratar leucemia, câncer sólido eleucemia, linfoma ou tumores sólidos em umhumano, e para fabricar uma composiçãofarmacêutica estéril, e, a respectiva composiçãofarmacêutica estéril
DE69127175T2 (de) Antisens-Oligonukleotide zur Behandlung von Krebs
WO1997002046A3 (de) Saccharid-konjugate
DK0462145T3 (da) Covalente konjugater mellem lipid og oligonucleotid
BR9107070A (pt) Processo para a preparação de derivados de quinazolina uteis para melhorar a atividade antitumoral.
ES2119738T3 (es) Profarmacos de etoposido de glicosilo, procedimiento para su preparacion y su aplicacion en combinacion con conjugados enzimaticos funcionalizados, especificos de tumores.
HUT51594A (en) Process for production of celates and their complexes containing ortolizating functional groups, compositions containing such active substances and process for production of conjugates consisting of one complex and linked to it antibody or fragment of antibody
RU92016354A (ru) Композиция, способы лечения, способ предупреждения рецидива, способ усиления цитотоксической активности иммунотоксина, способ усиления цитотоксического действия конъюгата
ES2113376T3 (es) Conjugados de anticuerpos para tratamiento de enfermedades neoplasticas.
ES2064613T3 (es) Produccion de agentes citotoxicos.
NZ309171A (en) use of apoptin as an antitumour agent which specifically kills tumour and not normal cells
GB9509888D0 (en) Terpenoidic derivatives useful as antitumour agents
ES2016464A6 (es) Procedimiento para preparar derivados de 2', 5' -oligoadenilato.
IL79260A (en) Process and composition for activation of immune response cells to be used in the treatment of cancer,non-malignant tumors,infections,and immune deficiencies
DE69009765T2 (de) Kynurensäurederivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 423747

Country of ref document: ES